<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03107390</url>
  </required_header>
  <id_info>
    <org_study_id>PI2013_843_0015</org_study_id>
    <nct_id>NCT03107390</nct_id>
  </id_info>
  <brief_title>Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease</brief_title>
  <acronym>NT-pro-MICI</acronym>
  <official_title>Evaluation of NT-proBNP in Chronic Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NT-proBNP is a major diagnostic and prognostic marker in cardiology, but it is also a new
      marker for biological inflammation, especially in rheumatology.

      Its evaluation in chronic inflammatory bowel disease was carried out in a preliminary study,
      the OPERA study where in a population of 12 patients showed an increase in NT-proBNP
      correlated with the biological and endoscopic activity of the disease. This larger study is
      therefore a pilot study that could see NTproBNP as a new biomarker of inflammation in MICI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2013</start_date>
  <completion_date type="Anticipated">June 30, 2029</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood level of NTproBNP.</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>NT-pro-BNP</condition>
  <arm_group>
    <arm_group_label>Patients with CD or RCH</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>The control population</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Evaluate the blood level of NTproBNP</intervention_name>
    <description>Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.</description>
    <arm_group_label>Patients with CD or RCH</arm_group_label>
    <arm_group_label>The control population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects (age 18 years)

          -  MICI Group: Patients monitored for probable HC or MC

          -  Control group: Patients referred for consultation in gastroenterology with a clinical
             and endoscopic picture eading to the diagnosis of TF I

          -  Person who agreed to participate in the study

          -  Patient covered by social insurance

        Exclusion Criteria:

          -  Causes of increased concentrations of natriuretic peptides: acute heart failure, acute
             or chronic pulmonary disease with right ventricular repercussion, valvulopathies,
             primary or secondary HVG, atrial fibrillation cardiac arrhythmia, chronic systolic
             dysfunction, hyperthyroidism, Addison's disease, hyperaldosteronism Primary, diabetes,
             cirrhosis with ascites, cancers, chronic renal insufficiency.

          -  Inflammatory and autoimmune diseases (excluding MC and RCH), chronic inflammatory
             syndrome

          -  Ongoing treatment that may affect the concentration of natriuretic peptides: ACE
             inhibitor, angiotensin II receptor antagonists, diuretics

          -  Patient deprived of liberty or protected major (under guardianship or curatorship)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jean-Louis DUPAS, PhD</last_name>
    <phone>+33322628208</phone>
    <email>dupas.jean-louis@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <state>Picardie</state>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Louis DUPAS, PhD</last_name>
      <phone>+33322668208</phone>
      <email>dupas.jean-louis@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

